MX1 and acute myeloid leukemia: Given that chemotherapy remains the standard therapy for AML, we then tested the activity of miRisten combined with a chemotherapy “5 + 3” regimen using Ara-C (50 mg/kg/day, 5 days) and DNR (1.5 mg/kg/day, 3 days) in a CM AML mouse model with a tdTomato+ Cre-reporter (Cbfb56M/+/Mx1-Cre/tdTomato+), which developed transplantable AML 3–6 months after poly(I:C) induction.